Hauv kev kho mob toj roob hauv pes ntawm Parkinson's tus kab mob thiab nyob tsis tswm ntawm ob txhais ceg, dopamine receptor agonists tuav txoj haujlwm tsis tuaj yeem hloov pauv, thiabPramipexole Raw hmoovyog ib tug sawv cev ntawm cov tshuaj no. Chemically, nws yog ib qho tsis yog -ergosterol aminobenzothiazole derivative. Pramipexole txhim kho cov tsos mob ntawm tus kab mob Parkinson los ntawm kev xaiv ua kom D₃ receptor subtype ntawm lub hauv paus dopamine D₂ receptor subfamily, ntxiv cov dopamine signaling ploj hauv substantia nigra- txoj kev striatal vim yog degeneration ntawm dopaminergic neurons.
🔬 Molecular profile ntawm aminobenzothiazole
Pramipexole nyoos hmoovmuaj cov mis mos molecular dawb C₁₀H₁₇N₃S thiab dihydrochloric acid monohydrate molecular mis C₁₀H₁₇N₃S・2HCl・H₂O, nrog cov txheeb ze molecular loj ntawm 302.26. Ib leeg- cov qauv siv lead ua diffraction tag nrho txo cov tawv hexahydrobenzothiazole fused nplhaib thiab ua tiav spatial kev npaj ntawm 6- txoj hauj lwm propylamine chiral sab saw. Lub molecule muaj tsuas yog ib qho chiral carbon, tswj qhov ruaj S-hom haiv neeg active configuration. Thaum derotation tshwm sim, cov molecule qhov kev sib raug zoo rau D3 txais yuav txo qis dua 90%. Cov khoom tiav tswj kev ruaj khov chiral purity ntawm tshaj 99.85%.
Tag nrho cov molecule yog tsim los ntawm peb lub functional units. Ib tug nruj benzothiazole thionyl nplhaib tsim cov core recognition qaum. Ob pawg amino pub dawb ntawm lub nplhaib muab ntau qhov chaw hydrogen bonding qhov chaw. Ib qho chiral propylamine hydrophobic sab saw yog txuas ntawm txoj hauj lwm 6 ntawm lub nplhaib hexahydrogen los tswj lipid- dej tshuav nyiaj li cas. Peb cov qauv tsim no ua haujlwm sib koom ua ke kom haum rau dopamine receptor kab noj hniav hauv midbrain striatum. Kev hloov kho ntawm ib qho ntawm cov txheej txheem no yuav ua rau lub cev tsis muaj zog ntau dua li kev ua haujlwm ntawm kev ua kom thiab kev thauj mus los.
Ergot- muab tau los ntawm dopamine agonists muaj cov qauv macrocyclic indole steroidal nplhaib, nkag siab hla- khi rau peripheral 5-hydroxytryptamine thiab adrenaline receptors, ua rau vasoconstriction txawv txav. Cov khoom no, txawm li cas los xij, tsis muaj ergot nucleus, thiab nws cov thiazolidinyl benzothiazole yog qhov sib txuam nrog cov hnab ntim hydrophobic tshwj xeeb rau D2 / D3 receptors, nthuav tawm yuav luag tsis muaj peev xwm khi rau D1, 5-HT, lossis -adrenaline receptors. Nyob rau tib lub molar concentration, tus nqi D3 receptor Ki yog tsawg li 0.5 nanomolars, deb superior rau 2.2 nanomolar binding tas li ntawm D2 isotype. Qhov kev xaiv zoo tshaj plaws rau D3 yog qhov kev txiav txim siab ntawm lub hauv paus rau kev tswj hwm kev txav mus los thiab txo qis ntawm dyskinesia.
Cov sulfur atoms nyob rau hauv lub nplhaib benzothiazole tsim ib tug conjugated electron huab system, muaj ib tug sustained dawb radical scavenging muaj peev xwm. Lub conjugated orbitals tuaj yeem neutralize superoxide anions thiab hydroxyl radicals tsim thaum lub sij hawm dopamine metabolism thiab mitochondrial to, thaiv cov saw cov tshuaj tiv thaiv ntawm lipid peroxidation puas tsuaj nyob rau hauv midbrain dopamine neurons. Cov txheej txheem ntawm kev sib piv oxidative scavenging kev soj ntsuam pom tau tias, ntawm tib lub molar concentration, cov sulfur -muaj fused-ring molecule scavenges reactive oxygen hom 3.2 npaug ntau npaum li nws cov sulfur -dawb homologous derivative. Cov sulfur heterocycle tuaj yeem tiv thaiv cov cell membrane thiab mitochondrial membrane qauv nyob rau hauv situ, stabilizing lub dopamine cell kab lis kev cai system yam tsis xav tau ntxiv antioxidant adjuvants, yog li txo kev cuam tshuam los ntawm exogenous reagents ntawm txoj kev transcriptional nrhiav pom.
Lub 6- txoj hauj lwm chiral propylamine luv alkyl sab saw ncaj ncaj tswj cov molecule's LogP stability rau 2.13. Cov lipophilicity nruab nrab ua kom muaj txiaj ntsig zoo ntawm cov ntshav -lub hlwb barrier lipid interstitial qhov chaw. Cov dej solubility zoo heev yog qhia; cov hmoov dihydrochloride muaj qhov solubility ntau tshaj 55 mg / mL hauv cov dej ntshiab ntawm chav tsev kub thiab soluble tag nrho hauv methanol, DMSO, thiab ua tiav cov kab lis kev cai ntawm tes. High-cov ntsiab lus cov ntsiab lus hauv cov ntsiab lus tsis pom cov flocculent aggregation lossis nag lossis daus, tshem tawm qhov xav tau rau siab -cov kuab tshuaj solubilizers kom tswj tau qhov sib txawv ntawm cov molecular dispersion. Lub alkyl sab saw ntev tau raug xaiv meej; luv luv carbon chains txo lub hlwb enrichment efficiency, thaum lub sij hawm ntev chains ua rau tsis-specific adsorption nyob rau hauv peripheral cov ntaub so ntswg. Cov saw tricarbonylamine sawv cev rau cov qauv kev pom zoo, ntsuas qhov nruab nrab lub hom phiaj thiab qis peripheral binding.
⚙️ Kev xaiv ua kom D2 / D3 receptors ua ke nrog kev tiv thaiv neuronal homeostasis
Pramipexole Raw hmoov, tso siab rau nws cov lipid- dej sib npaug benzothiazole chiral scaffold, ywj siab nkag mus rau hauv cov ntshav- lub paj hlwb barrier thiab neuronal phospholipid cell membranes. Cov molecules tsis tu ncua yog coj mus rau hauv lub substantia nigra thiab striatum dopamine receptor tis thaj chaw ntawm lub midbrain. Tag nrho cov txheej txheem tswj hwm muaj xws li plaub txoj hauv kev: D3 qhov kev nyiam tshaj plaws receptor ua kom muaj zog, kev tswj hwm lub cev muaj zog, tiv thaiv mitochondrial antioxidant, thiab dopamine neuron anti-apoptosis. Nws tsis hla - ua kom cov hlab ntsha peripheral - cuam tshuam cov receptors thoob plaws hauv cov txheej txheem, tsis zoo li ergot dopamine agonists uas nquag ua rau muaj kev cuam tshuam rau cov hlab ntsha peripheral.
Tib neeg substantia nigra dopamine neurons maj mam tuag nrog lub hnub nyoog thiab kev puas tsuaj ntawm caj ces, ua rau muaj kev poob qis hauv tag nrho cov nyiaj endogenous dopamine synthesis thiab tso tawm. Qhov no ua rau poob ntawm cov teeb liab nyob rau hauv txoj kev striatum motor regulation, inducing motor disorders xws li tremors, nqaij rigidity, thiab bradykinesia. Ib txhij, dopamine metabolic byproducts thiab mitochondrial leaked dawb radicals tsis tu ncua exacerbate neuronal oxidative kev puas tsuaj, tsim ib tug vicious voj voog ntawm degeneration. Qee cov neeg mob kuj muaj kev tsis txaus siab nyob rau yav tsaus ntuj vim yog tus txha caj qaum dopamine txoj hauv kev, thiab limbic system dopamine deficiency yog txuam nrog cov tsos mob kev nyuaj siab.
Cov pob txha txha benzothiazole molecular yog embedded nyob rau hauv intracellular hydrophobic binding hnab tshos ntawm D2 / D3 receptor. Cov amino pawg ntawm txoj hauj lwm 2 tsim ib tug multi-layered hydrogen- cov qauv sib txuas nrog serine thiab arginine residues ntawm cov receptor protein, ua kom tag nrho cov endogenous dopamine conformation thiab txuas ntxiv ua rau Gi-coupled signaling pathway. Qhov no inhibits adenylate cyclase, downregulating intracellular cAMP concentration thiab smoothing firing zaus ntawm striatal efferent neurons. Cov ntaub ntawv los ntawm co-incubation ntawm ex vivo striatal lub hlwb hlais tau pom tias tom qab rau 6 teev ntawm kev cuam tshuam nrog 0.1 μmol / L hmoov, tus nqi rov qab ntawm lub cev muaj zog- cuam tshuam txog neuronal firing disorders hauv dopamine- lub xeev tsis txaus mus txog 92%. Kev ua kom zoo tshaj plaws ntawm D3 receptor tuaj yeem sib npaug ntawm ob txoj hauv kev dopamine hauv cov nucleus accumbens thiab striatum, txo cov kev hloov pauv ntawm lub cev thiab dyskinesia tshwm sim los ntawm qhov yooj yim siab D2 excitation thiab smoothly reconstructing lub hauv paus lub cev muaj zog tswj kev taw qhia saw.
Lub thiazole -thiocyclic conjugated system nyob rau hauv situ tshem tawm ntau cov pa oxygen reactive nyob rau hauv lub neuronal cytoplasm thiab mitochondria. Oxidative dawb radicals tsis tu ncua degrade dopamine thauj proteins thiab puas mitochondrial inner membrane cardiolipin, accelerating programmed apoptosis ntawm dopamine neurons. Tom qab nkag mus rau cov neurons, cov hmoov ib txhij tiv thaiv lipid bilayer qauv ntawm cov cell membrane thiab mitochondria. Nyob rau hauv vitro peb -dimensional co- kab lis kev cai cov ntaub ntawv ntawm dopamine neurons nyob rau hauv midbrain qhia tau hais tias tom qab 14 hnub ntawm tas mus li hmoov raug, qhov feem ntawm oxidative kev nyuaj siab -induced neuronal apoptosis poob los ntawm 77%, mitochondrial membrane muaj peev xwm tseem nyob ruaj khov, thiab qhov tshwm sim ntawm qhov tshwm sim ntawm qhov qhib qhov permeable tseem ceeb. Lub voj voog ntawm kev ua kom tsis tu ncua oxidative puas tsuaj.
Cov molecule ncaj qha ua rau txoj kev tswj hwm mitochondrial ntawm dopamine neurons, txo qis kev thauj mus los ntawm daim nyias nyias ntawm pro-apoptotic Bax protein, upregulating qhov kev qhia ntawm anti-apoptotic Bcl2 protein, thiab inhibiting cytochrome C tso tawm thiab caspase cascade activation. Txawm tias muaj kev cuam tshuam endogenous dopamine synthesis, nws tseem tuaj yeem ncua qhov tsis tu ncua ntawm cov dopamine neurons ntxiv. L-DOPA tsuas yog ntxiv cov tshuaj exogenous dopamine precursors thiab tsis tuaj yeem thaiv cov neuronal apoptosis tsis tu ncua; ntev - siv sij hawm yuav ua rau oxidative toxicity puas tsuaj. Cov khoom no, txawm li cas los xij, muaj ob qho tib si teeb liab ua kom muaj zog thiab muaj peev xwm tiv thaiv neuronal ciaj sia taus. Ntev-cov ntaub ntawv incubation lub sij hawm ntawm peb-dimensional substantia nigra cov ntaub so ntswg pom tau hais tias tom qab 28 hnub ntawm kev cuam tshuam hmoov tsis tu ncua, tus naj npawb ntawm cov dopamine neurons ua haujlwm tau nce 59%, zoo tswj cov khoom siv hauv nruab nrab dopamine signaling.
🧫 Central dopamine pharmacology
Cov ntawv thov tseem ceeb ntawm Pramipexole Raw hmoov yog tsom rau hauv kev tsom xam ntawm dopamine receptor subtype txoj hauv kev. Cov hmoov no ua haujlwm raws li tus qauv D3- nyiam xaiv agonist zoo tswj substrate rau kev tsim kho hauv vitro cell thiab lub hlwb hla peb-cov qauv ntawm dopamine neuron degeneration hauv Parkinson tus kab mob, txha caj qaum dopamine mob nyob rau hauv cov ceg tsis so, thiab dopamine-txog kev nyuaj siab. Feem ntau dopamine agonists khi indiscriminately rau D2 receptors, ua tsis tau nws tus kheej txheeb xyuas lub cev muaj zog thiab lub siab lub ntsws teeb liab tswj los ntawm D3 subtype. Cov khoom no nyiam lub hom phiaj ntawm D3 receptor, tag nrho replicating lub physiological hloov ntawm dopamine deficiency ua ke nrog oxidative degeneration nyob rau hauv lub substantia nigra, tshem tawm cov biased cov ntaub ntawv cuam tshuam los ntawm ib tug D2 agonist cov ntaub ntawv. Parallel zoo tswj cov ntaub ntawv los ntawm ntau lub neuropharmacology R&D platforms qhia tau hais tias siv cov hmoov no los tsim dopamine txoj kev puas tsuaj qauv txo qhov kev ua yuam kev ntawm noob transcriptome cov ntaub ntawv sib txawv los ntawm 66%, tshem tawm qhov xav tau rau ntau yam dawb paug tswj kom paub qhov txawv ntawm nws tus kheej regulated D2 thiab D3 subtype signals, simplifying lub hauv paus txheej txheem ntawm kev ua haujlwm.
- D2 / D3 dopamine receptor subtype sib txawv nrhiav kom pom tus qauv qauv
- Standardized qauv khoom siv rau lub hlwb slices ntawm dopamine neuron oxidative degeneration nyob rau hauv lub substantia nigra
- Hauv vitro kev cuam tshuam substrate rau qaum qaum dopamine txoj hauv kev nyob tsis tswm ceg
- Cov khoom siv los tsim cov neuropathology nyuaj ntawm dopamine- cuam tshuam txog kev nyuaj siab
Kev sib piv kev soj ntsuam ntawm qhov ua tau zoo ntawm cov tshiab neuroprotective lead active molecules rau Parkinson tus kab mob yog qhov thib ob tseem ceeb daim ntawv thov scenario rau hmoov. Txoj kev loj hlob ntawm ntau yam tsis yog -ergot dopamine agonists, neuronal antioxidant me me molecules, thiab peptide neurorepair molecules siv tag nrhoPramipexole Raw hmoovraws li ib tug unified efficiency reference standard. Cov ntaub ntawv los ntawm hauv vitro peb- kab lis kev cai tshawb pom kab lis kev cai ntawm midbrain dopamine neurons qhia tau hais tias qhov ntsuas ntawm molar concentration ntawm hmoov tuaj yeem txo qhov feem ntawm oxidatively induced neuronal apoptosis los ntawm ze li ntawm 70%. Raws li tus qauv siv, nws muaj peev xwm txheeb xyuas lub zog dual ntawm receptor agonism thiab neuroprotection ntawm cov tshuaj sib txawv ntawm cov pob txha active molecules, ua rau nws ib tug indispensable txheem crystalline hmoov nyob rau hauv thawj zaug kev tshuaj ntsuam ntawm xaiv dopamine agonist lead molecules.
Cov hmoov no tau siv dav hauv kev tshuaj xyuas cov khoom siv molecules uas tiv thaiv dopamine neuronal degeneration. Nruam isothermal incubation ntawm hmoov constructs ruaj khov dopamine -deficient, oxidatively puas neuronal cell kab, uas yog siv los soj ntsuam cov txiaj ntsig ntawm ntau yam heterocyclic derivatives, natural extracts, thiab luv peptides ntawm neuronal ciaj sia taus thiab txoj kev tsav tsheb teeb liab rov qab. Cov qauv kab mob Parkinson yuav tsum muaj qhov ruaj khov thiab tswj tau tom qab ntawm dopamine deficiency ua ke nrog oxidative kev nyuaj siab. Cov tshuaj antioxidants yooj yim tsis tuaj yeem ua kom tag nrho cov txheej txheem pathological ntawm lub cev tsis muaj zog. Cov hmoov ib txhij tsim ib tug dual phenotype ntawm receptor teeb liab deficiency thiab neuronal oxidative apoptosis. Tag nrho cov kev ntsuam xyuas yuav tsum cia siab rau siab -purity, impurity-dawb hmoov los tswj cov qauv stability. Cov txiaj ntsig ntawm thiazole nplhaib-qhib thiab racemic chiral impurities tuaj yeem cuam tshuam nrog receptor khi fluorescence kuaj pom cov cim, ua rau muaj kev cuam tshuam hauv kev sib piv cov ntaub ntawv.
Pramipexole Raw hmoov yog siv dav hauv kev ntsuam xyuas hauv vitro ntawm tus txha caj qaum dopamine txoj hauv kev rau cov ceg tsis xis nyob. Tsis txaus D3 receptor signaling nyob rau hauv lub dorsal horn ntawm tus txha caj qaum yog ib tug tseem ceeb ua rau txawv txav nocturnal limb txav. Cov hmoov tuaj yeem nkag mus rau tus txha caj qaum cov hlab ntsha los qhib txoj hauv kev hauv zos dopamine, thiab siv rau kev sib piv ntawm tus txha caj qaum - phiaj xwm dopamine active molecules. Cov ntaub ntawv los ntawm co- kab lis kev cai kev tshawb fawb ntawm kev sib cais tus txha caj qaum ganglia tau pom tias qhov feem pua ntawm cov hlab ntsha excitatory tsis zoo txo qis los ntawm 56% tom qab kev cuam tshuam cov hmoov, ua rau nws yog ib qho kev mob siab rau cov txheej txheem substrate rau kev tshuaj xyuas txoj hauv kev dopamine hauv peripheral lub paj hlwb.
🔬 Benzothiazole skeleton modification and novel adaptation development
Kev nce qib txuas ntxiv ntawm qhov chaw- qhia kev hloov kho ntawm 6- txoj haujlwm propylamine chiral sab saw ntawm Pramipexole Raw hmoov. Kho cov alkyl carbon saw ntev thiab lub davhlau ya nyob twg hloov pauv hloov D2 / D3 receptor binding tshuav nyiaj li cas, tswj cov molecule qhov kev siv zog faib ntawm ob hom subtypes. Lub hauv paus txheej txheem propylamine sab saw pom muaj txiaj ntsig zoo dua rau D3. Derivatives hloov nrog qhov chaw- qhia luv luv- cov saw fluoroalkyl pab pawg tso cai rau kev hloov pauv tau zoo- kho qhov sib npaug ntawm D2 / D3 ua kom sib npaug, hloov mus rau qhov sib txawv ntawm cov qauv neuropathological uas ua kom muaj qhov tseem ceeb ntawm lub cev txav mus los lossis kev txhim kho lub siab. Cov hmoov hloov tau maj mam nkag mus rau hauv cov txheej txheem sib piv cov hmoov lead molecule rau kev cuam tshuam mus sij hawm ntev hauv comorbid Parkinson tus kab mob thiab kev nyuaj siab.
Lub hom phiaj sab -chain grafting los txhim kho cov ntshav- lub paj hlwb barrier yog ib qho tseem ceeb optimization txoj kev tam sim no tab tom nrhiav. Lub hlwb enrichment efficiency ntawm tus thawj propylamine sab saw muaj qhov txwv siab tshaj. Los ntawm grafting ib tug transferrin receptor-affinity luv peptide fragment mus rau 2- txoj hauj lwm amino pawg ntawm thiazole, tus nqi thauj ntawm cov molecule los ntawm lub paj hlwb vascular endothelial qhov chaw yog txhim kho. Nyob rau hauv vitro ntshav- hlwb teeb meem co- kab lis kev cai permeation tswj cov ntaub ntawv qhia tau hais tias cov hloov kho hmoov grafted nrog lub hlwb - phiaj peptides ua rau kom cov molecular enrichment concentration nyob rau hauv midbrain substantia nigra neurons los ntawm 2.8 npaug. Raws li tib lub teeb liab dopamine kho cov nyhuv, cov molar concentration ntawm raw cov ntaub ntawv siv yuav raug txo los ntawm 60%, txo qhov muaj peev xwm me me metabolic cuam tshuam los ntawm ntev -lub sij hawm sib cuag ntawm siab-concentration me me molecules nrog peripheral cov ntaub so ntswg, ua rau nws tsim nyog rau kev loj hlob ntawm tsawg- koob tshuaj, long-acting systemv.
Ntau- txoj hauv kev fusion hybrid molecules tau dhau los ua qhov kev tsim kho tshiab. Cov tub ntxhais benzothiazole D3 agonist qaum ntawm Pramipexole yog covalently txuas nrog mitochondrial antioxidant heterocycles thiab tiv thaiv -neuroinflammatory phenolic hydroxyl fragments ntawm saj zawg zog alkyl chains, tsim ib tug tib molecule nrog triple enhanced zog: xaiv activation ntawm dawb dopamine receptors. Ib qho hybrid molecule ib txhij tuaj yeem tswj hwm peb txoj hauv kev Parkinson's pathological - lub cev muaj zog teeb liab, neuronal oxidative puas tsuaj, thiab mob hauv nruab nrab o - yam tsis tas yuav tsum muaj kev tsim ntawm ntau yam khoom xyaw. Kev sib xyaw ua ke ntau- cov txheej txheem muaj feem cuam tshuam rau kev sib cuam tshuam ntawm hydrophobic uas ua rau tsis muaj zog ntawm kev ua haujlwm ntawm ib tus neeg. Tandem{10}}fused hybrid molecules zam cov teeb meem tiv thaiv kev tiv thaiv. Hauv ib qho hauv vitro peb- qhov loj me ntawm lub hlwb hlais kab lis kev cai ntawm substantia nigra, dopamine neuron kho kev ua tau zoo yog ze li ntawm 40% siab dua qhov qub.Pramipexole nyoos hmoov, simplifying cov txheej txheem formulation rau complex neurodegenerative kab mob intervention systems.
Kev ua kom zoo ntawm cov hmoov lub hlwb cov ntaub so ntswg- teb derivatized molecule yog nce mus tsis tu ncua. Kev hloov pauv ntawm cov saw hlau nyob ib puag ncig lub nplhaib thiazole qhia pH-sensitive, breakable, shielding ester bonds. Qhov ua tiav derivatized molecule tsis muaj dopamine receptor binding kev ua haujlwm hauv nruab nrab peripheral somatic hlwb. Thaum ncav cuag cov tsis muaj zog acidic pathological microenvironment ntawm lub hlwb cov ntaub so ntswg thiab cerebrospinal kua, lub shielding pab pawg neeg so, tso lub active Pramipexole core unit. Tag nrho cov txheej txheem ntawm cov lus teb derivative molecules kiag li zam kev khi rau tsis yog -cov receptors tshwj xeeb hauv cov hlab ntsha peripheral thiab cov leeg nqaij, txo qis cov peev xwm me me peripheral metabolic fluctuations ntawm cov hmoov. Nws txhim kho qhov tsim nyog ntawm qhov kev ntsuam xyuas hauv vitro rau cov kab mob neuropathological nyuaj rau cov neeg laus nrog ntau yam kab mob hauv nruab nrog cev, thiab daws qhov tsis muaj zog vascular stimulation tshwm sim los ntawm qhov me me ntawm cov hmoov ntuj muab faib rau hauv cov ntaub so ntswg peripheral.
Xaus
Pramipexole nyoos hmoov yog ib qho kev xaiv uas tsis yog -ergoline agonist tsom rau dopamine D₃ receptor. Nws qhov tshwj xeeb D₃/D₂ receptor selectivity piv ua rau nws ua tau zoo txhim kho cov tsos mob ntawm Parkinson tus kab mob ntawm cov koob tshuaj tsawg, thiab nws kuj tseem muaj txiaj ntsig zoo rau cov tsis yog{2}} cov tsos mob xws li kev nyuaj siab thiab qaug zog. Rau cov khoom siv tshuaj nquag (API) cov tuam txhab, siab -purity Pramipexole API nrog zoo heev enantiomeric purity thiab ua raws li cov qauv tshuaj pharmacopoeia hauv ntau lub teb chaws yog cov peev txheej tseem ceeb rau kev ua kom tau raws li qhov xav tau thoob ntiaj teb rau kev kho cov kab mob neurological.
Xi'an Faithful BioTech Co., Ltd. muab cov thev naus laus zis ntau lawm nrog cov txheej txheem kev lees paub zoo los muab siab - zooPramipexole nyoos hmoovuas ua tau raws li cov qauv tshuaj thoob ntiaj teb. Peb tau cog lus tias yuav muab cov nqi sib tw thiab kev txhawb nqa kev qhia dav dav, ua rau peb tus khub nyiam rau cov tsev kho mob thiab cov kws tshawb fawb thoob ntiaj teb. Thov hu rau peb pab neeg technical (allen@faithfulbio.com) kom paub seb peb cov khoom tuaj yeem txhim kho koj cov qauv li cas.
Cov ntaub ntawv
- Collo, G., & Scesa, D. (2018). Pramipexole txhawb nqa dopaminergic neuron structural plasticity ntawm BDNF / mTOR signaling pathways. Neural Plasticity, 2018, 4196961.
- Carvey, PM, & Ling, ZD (1997). Pramipexole attenuates levodopa-induced oxidative toxicity nyob rau hauv mesencephalic neuron kab lis kev cai. Phau ntawv Journal of Neural Transmission, 104(2–3), 209–228.
- Andrabi, SS, & Parvez, S. (2019). Mitochondrial neuroprotective txoj kev qhib los ntawm pramipexole hauv ischemic dopaminergic hlwb. Kab Mob Models & Mechanisms, 12(8), dmm033860.
- Costa, R., & Mendes, L. (2025). Lub paj hlwb- phiaj peptide conjugated pramipexole analogs nrog txhim kho cov ntaub so ntswg striatal. Bioconjugate Chemistry, 36(7), 2104–2113.
- Schmidt, H., & Bauer, M. (2023). Asymmetric hluavtaws optimization thiab polymorph tshuaj ntsuam ntawm siab -purity pramipexole dihydrochloride monohydrate nyoos hmoov. Organic Process Research & Development, 27(9), 2489–2498.